Effect of Antinuclear Antibodies on Pharmacokinetics of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease

Overview

Journal Int J Colorectal Dis

Specialties Gastroenterology
General Surgery

Date 2022 Jan 11

PMID 35013823

Authors

Eirini Theodoraki

Eleni Orfanoudaki

Kalliopi Foteinogiannopoulou

Nikolaos-Panagiotis Andreou

Maria Gazouli

Ioannis E Koutroubakis

Affiliations

Soon will be listed here.

Abstract

Purpose: The detection of antinuclear antibodies (ANA) in serum of patients with inflammatory bowel disease (IBD) has been associated with a worse response to anti-TNF therapy and the development of cutaneous or arthritic manifestations. The aim of this study was to investigate a possible association of serum ANA with infliximab (IFX) and adalimumab (ADA) trough levels (TLs) and anti-drug antibodies in IBD patients treated with IFX or ADA.

Methods: Consecutive IBD patients under maintenance therapy with IFX or ADA in whom there was at least one available measurement of anti-TNF TLs, antibodies to IFX or ADA, and ANA in serum were included. The correlation of ANA positivity with demographics, clinical characteristics, treatment, TLs and anti-drug antibodies, of all patients was analyzed.

Results: One hundred two IBD patients under maintenance therapy with IFX or ADA were enrolled. Of these, 53 (52%) were ANA positive with 28 (27.5%) positive also to anti-ds-DNA in serum. In the univariate analysis ANA positivity was found to be correlated with age (P = 0.008), female gender (P = 0.03), duration of treatment (P = 0.06), arthralgias (P = 0.04) and TLs (P = 0.005). However, in multivariate logistic regression analysis only age and TLs remained significantly associated with the presence of ANA positivity (P = 0.04 and P = = 0.006, respectively). No significant association of ANA positivity with the development of cutaneous or rheumatological manifestations was found.

Conclusions: In IBD patients under maintenance therapy with anti-TNF ANA positivity is associated with lower TLs. The clinical significance of this finding remains to be defined in future larger prospective studies.

Citing Articles

Adalimumab Autoantibodies in Uveitis Patients: Do We Need Routine Drug Monitoring?.

Zur Bonsen L, Knecht V, Rubsam A, Pohlmann D, Pleyer U Biomedicines. 2025; 12(12.

PMID: 39767689 PMC: 11673539. DOI: 10.3390/biomedicines12122782.

References

Shihab Z, Yeomans N, De Cruz P . Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis. J Crohns Colitis. 2016; 10(8):979-88. DOI: 10.1093/ecco-jcc/jjv234. View

Scheinfeld N . A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat. 2004; 15(5):280-94. DOI: 10.1080/09546630410017275. View

Hommes D, Oldenburg B, van Bodegraven A, van Hogezand R, de Jong D, Romberg-Camps M . Guidelines for treatment with infliximab for Crohn's disease. Neth J Med. 2006; 64(7):219-29. View

Beigel F, Schnitzler F, Laubender R, Pfennig S, Weidinger M, Goke B . Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010; 17(1):91-8. DOI: 10.1002/ibd.21362. View

Fiorino G, Danese S, Pariente B, Allez M . Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev. 2013; 13(1):15-9. DOI: 10.1016/j.autrev.2013.06.005. View

Pink A, Fonia A, Allen M, Smith C, Barker J . Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol. 2009; 162(4):780-5. DOI: 10.1111/j.1365-2133.2009.09563.x. View

Mori A, Saito T, Takahashi M, Shibata M, Tsuji G, Hatachi S . Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis. PLoS One. 2020; 15(12):e0243729. PMC: 7735569. DOI: 10.1371/journal.pone.0243729. View

Santos-Antunes J, Nunes A, Lopes S, Macedo G . The Relevance of Vitamin D and Antinuclear Antibodies in Patients with Inflammatory Bowel Disease Under Anti-TNF Treatment: A Prospective Study. Inflamm Bowel Dis. 2016; 22(5):1101-6. DOI: 10.1097/MIB.0000000000000697. View

Coutzac C, Chapuis J, Poullenot F, Chabrun E, Capdepont M, Blanco P . Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study. J Crohns Colitis. 2015; 9(11):982-7. DOI: 10.1093/ecco-jcc/jjv159. View

10.

Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N . Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003; 125(1):32-9. DOI: 10.1016/s0016-5085(03)00701-7. View

11.

Soto M, Hernandez-Becerril N, Perez-Chiney A, Hernandez-Rizo A, Telich-Tarriba J, Juarez-Orozco L . Predictive value of antinuclear antibodies in autoimmune diseases classified by clinical criteria: Analytical study in a specialized health institute, one year follow-up. Results Immunol. 2015; 5:13-22. PMC: 4625361. DOI: 10.1016/j.rinim.2013.10.003. View

12.

Tan E, FELTKAMP T, Smolen J, Butcher B, Dawkins R, Fritzler M . Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997; 40(9):1601-11. DOI: 10.1002/art.1780400909. View

13.

Papamichael K, Cheifetz A, Melmed G, Irving P, Vande Casteele N, Kozuch P . Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019; 17(9):1655-1668.e3. PMC: 6661210. DOI: 10.1016/j.cgh.2019.03.037. View

14.

Theodoraki E, Orfanoudaki E, Foteinogiannopoulou K, Legaki E, Gazouli M, Koutroubakis I . Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?. Intest Res. 2020; 19(4):461-467. PMC: 8566825. DOI: 10.5217/ir.2020.00042. View

15.

Greener T, Kabakchiev B, Steinhart A, Silverberg M . Higher Infliximab Levels Are Not Associated With an Increase in Adverse Events in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018; 24(8):1808-1814. DOI: 10.1093/ibd/izy066. View

16.

Danese S, Fiorino G, Reinisch W . Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy. Aliment Pharmacol Ther. 2011; 34(1):1-10. DOI: 10.1111/j.1365-2036.2011.04679.x. View

17.

Picardo S, So K, Venugopal K . Anti-TNF-induced lupus in patients with inflammatory bowel disease. JGH Open. 2020; 4(3):507-510. PMC: 7273700. DOI: 10.1002/jgh3.12291. View

18.

Kocharla L, Mongey A . Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another?. Lupus. 2009; 18(2):169-71. DOI: 10.1177/0961203308093922. View

19.

Frederiksen M, Ainsworth M, Brynskov J, Thomsen O, Bendtzen K, Steenholdt C . Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis. 2014; 20(10):1714-21. DOI: 10.1097/MIB.0000000000000138. View

20.

Subramanian S, Yajnik V, Sands B, Cullen G, Korzenik J . Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis. 2010; 17(1):99-104. DOI: 10.1002/ibd.21370. View